SCHEMBL1335470

SCHEMBL1335470

N#C[C@@H]1C[C@H](F)CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13070113 1.00
SCHEMBL894918 1.00
Hydrochloric Acid SCHEMBL1153672 0.98
Bromide SCHEMBL27682610 0.98
SCHEMBL27558850 0.84 CTSC (0.39)
SCHEMBL1337026 0.75
SCHEMBL1676738 0.75
SCHEMBL1676884 0.75
SCHEMBL3159738 0.74
SCHEMBL14972886 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473285-B2 DCN-1 modulating compounds and methods of use thereof CELLARITY, INC. (US) 2025-11-18 US disclosed
US-12435087-B2 Modulators of DCN-1 and methods of use thereof CELLARITY, INC. (US) 2025-10-07 US disclosed
US-20250257063-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF THAMES PHARMA PARTNERS 2025-08-14 US disclosed
US-20250163058-A1 MODULATORS OF DCN-1 AND METHODS OF USE THEREOF THAMES PHARMA PARTNERS 2025-05-22 US disclosed
US-20250163057-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF THAMES PHARMA PARTNERS 2025-05-22 US disclosed
WO-2025096956-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF CELLARITY, INC. (US) 2025-05-08 WO disclosed
WO-2025096981-A1 MODULATORS OF DCN-1 AND METHODS OF USE THEREOF CELLARITY, INC. (US) 2025-05-08 WO disclosed
WO-2025090919-A1 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE PITON THERAPEUTICS, INC. (US) 2025-05-01 WO disclosed
WO-2025090920-A1 COMPOSITIONS AND METHODS FOR TREATING DYSFUNCTION OF GLUCOSE METABOLISM AND/OR REGULATION PITON THERAPEUTICS, INC. (US) 2025-05-01 WO disclosed
CN-114867719-A Pyrrolidine and piperidine compounds 柳韩洋行 2022-08-05 CN disclosed
US-20080076818-A1 NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2008-03-27 US disclosed
EP-1862457-A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors SmithKline Beecham Corporation (US) 2007-12-05 EP disclosed
US-20070265320-A1 Bicycloamide Derivative KYORIN PHARMACEUTICAL CO., LTD (JP) 2007-11-15 US disclosed
EP-1399433-B1 FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2007-08-22 EP disclosed
EP-1799639-A1 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION Glenmark Pharmaceuticals S.A. (CH) 2007-06-27 EP disclosed
US-7183290-B2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2007-02-27 US disclosed
US-7183290-B2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2007-02-27 US disclosed
EP-1717225-A1 BICYCLIC AMIDE DERIVATIVES Kyorin Pharmaceutical Co., Ltd. (JP) 2006-11-02 EP disclosed
WO-2006040625-A1 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION GLENMARK PHARMACEUTICALS S.A. (US) 2006-04-20 WO disclosed
WO-2003002531-A2 FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-01-09 WO disclosed